Background and objective: Tacrolimus has been widely used in recent years for treating allergic conjunctivitis, but there is currently no available meta-analysis regarding its therapeutic efficacy. This study systematically evaluated the effectiveness of tacrolimus in the treatment of allergic conjunctivitis.
Methods: Data obtained from literature searches of the PubMed, Cochrane Library, Embase, CNKI, and Wanfang databases were retrieved by combining medical subject words and free words. Literature was selected on the basis of established inclusion and exclusion criteria, and the extracted data were evaluated for risk of bias using RevMan 5.3 for meta-analysis.
Results: A total of 177 articles were retrieved, of which 5 articles were eventually selected, all of which involved tacrolimus treatment for vernal keratoconjunctivitis. A total of 203 samples were analysed. Results of the meta-analysis showed that the tacrolimus treatment group had significantly lower ocular objective sign scores (SMD -1.39, 95% CI -2.50 to -0.27; p<0.05) and had a significantly lower subjective symptom evaluation score (SMD -0.92, 95% CI -1.59 to -0.24; p<0.05) than the control group.
Conclusion: Current evidence shows that tacrolimus is effective in treating vernal keratoconjunctivitis.
Keywords: allergy and immunology; evidence-based medicine; hospital; ophthalmology; pharmaceutical preparations; pharmacy service.
© European Association of Hospital Pharmacists 2022. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ.